PerpEquities

Equity · Healthcare

Sino Biopharmaceutical Limited (SINOBIOPHARM) perpetual futures

SINOBIOPHARM perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade SINOBIOPHARMUSDT.

Sino Biopharmaceutical Limited is a China-focused research and development pharmaceutical conglomerate offering oncology, liver disease, respiratory, and surgery/analgesia medicines.

$0.7063-1.0%
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · Gate.io (SBP/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$0
Open interest
$7.7K
Best liquidity
$0
Gate.io
Tightest spread
+222.3 bps
Gate.io
Highest volume
$0
Gate.io
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $12.2M
OI / float
0.00%
Float $6.2B
Spot performance
1D-1.62%
5D+1.58%
1M+1.02%
6M+0.64%
YTD-11.57%
1Y-21.48%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
Gate.ioTradeSBP/USDTTrading$0.70630.0% APR
0.000% every 8h		+222.3 bps$0$0$7.7KUSDT25x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

No fresh book data: Gate.io

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

SINOBIOPHARM
Gate.io · SBP/USDT$0

Tightest spread

SINOBIOPHARM
Gate.io · SBP/USDT+222.3 bps

Highest volume

SINOBIOPHARM
Gate.io · SBP/USDT$0

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q2 '26 · filed 2026-06-30 · next report 2027-04-01 · Updated 6h ago
All financials →

Valuation & key figures

Market cap
$12.4B
Updated 6h ago
Revenue
$5B
Trailing 12 months
Revenue growth
+14%
Next fiscal year
Profit margin
+7.1%
P/E
34.9
Peer P/E -16.9
P/S
2.5
Peer P/E
-16.9
Similar listed perps
Free cash flow
$772.1M
Trailing 12 months
Net income
$357.3M
Trailing 12 months
Revenue estimate
$5.4B
Next fiscal year
Earnings
2027-04-01
Revenue est. $2.5B · Updated 6h ago
Dividend
$0.07
2026-09-01
Revenue (TTM)CN¥33.7B+10.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)29.8%+8.7 pp vs a year agoOperating income CN¥10B
Net income (TTM)CN¥2.39B-38.3% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)CN¥5.16B+78.7% vs a year agoCapex CN¥968M
Diluted EPS (TTM)CN¥0.13-38.8% vs a year agoSum of the last 4 quarters
Net cash-CN¥2.29B-129.1% vs a year agoCash + short-term investments - debt
  • Revenue growth steady: 10.6% year on yearQ2 '26 revenue CN¥9.72B, against an average of 10.2% over the four quarters before.
  • Operating margin 29.8% (TTM), +8.7 pp on a year agoOperating income grew 55.7% while revenue grew 10.3%.
  • 20.6% of pre-tax profit is eaten by non-operating lossesPre-tax income CN¥8.32B vs operating income CN¥10B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
  • Capex 2.9% of revenue (a year ago 0.9%)CN¥968M invested in the last 4 quarters (+257.4% on a year earlier). Free cash flow CN¥5.16B = 216.1% of net income.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates

Next catalyst

Catalysts

Earnings
2027-04-01
Revenue est. $2.5B · Updated 6h ago
Dividend
$0.07
2026-09-01

No unusual perp activity right now.

Reference data

Market context

Reference market

Closed
Hong Kong Stock Exchange
Regular hours
09:30 AM – 12:00 PM GMT+8
Next holiday
Dec 24, 2026 · Christmas Eve (half day)

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20260.04$5.4B+14%15
FY 20270.04$5.8B+22%15
FY 20280.04$6.3B+32%16
FY 20290.04$6.9B+45%13
FY 20300.04$7.6B+59%13
Q2 20270.06$2.1B+46%1

Company events

6
2027-04-01EarningsActual - / Estimate 0.11-
2026-09-01Dividend$0.07-
2026-08-19EarningsActual 0.22 / Estimate 0.14Beat
2026-06-24Dividend$0.05-
2026-03-26EarningsActual 0.01 / Estimate 0.07Miss
2025-08-29Dividend$0.05-

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
SMMT$14.2B--16.70.0%1TEM$14.3B9.5-76.7-12.5%17AKESO$10.1B19.8-71.4-28.0%2TWST$8.7B20.1-59.5-31.7%15OSCR$8.7B0.512.0+4.9%3ABVX$7.9B--17.0+17,488.9%1EXEL$17.7B7.120.5+35.5%1CAI$7B6.772.7+9.2%1

Company data

Company intelligence

Updated: Nov 2, 2026, 07:13 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
Chief executive
S. Y. Tse
Employees
22,838
IPO date
May 12, 2004
Country
HK
Exchange
Hong Kong Stock Exchange
Website
Altman Z-scorei2.67
Piotroski scorei6/9
Overall ratingiB+
Owner earningsiCN¥310.52MCN¥0.02 per share

Rating factors

Return on equityi
3
Return on assetsi
3
Debt to equityi
2
Price to earningsi
2
Price to booki
3
Market cap history
HK$87.90B-1.4%Aug 26 – Nov 26
HK$86.59BHK$96.72BHK$106.85BHigh: HK$106.85B · 2026-09-21Low: HK$86.59B · 2026-08-17Latest: HK$87.90B · 2026-11-02Aug 26Sep 26Oct 26Nov 26
Latest: HK$87.90B · 2026-11-02High: HK$106.85B · 2026-09-21Low: HK$86.59B · 2026-08-17
Largest fund holders
FundWeightShares held
VXUS0.02%142.8M
VWO0.06%136.6M
IEMG0.05%112.3M
2800.HK0.32%81.1M
AVEM0.09%38.5M
EIMI.L0.05%35.3M
EIMU.L0.05%35.3M
EIMU DE0.05%35.3M
BBAX0.26%28.8M
EEM0.05%25M
MCHI0.27%23.7M
VEU0.02%23M

Analyst track record

How the analysts covering SINOBIOPHARM have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings00
Analysts00
Buy / hold / sell––
Upgrades / downgrades / initiations0 / 0 / 00 / 0 / 0
Price targets hit / missed––
Avg. return after a rating (TipRanks)––
Best / worst call– / –– / –

After buy calls on this stock: not enough measured cases yet

TipRanks data · computed Nov 5, 2026 · 0 ratings

Frequently asked questions

Where can I trade SINOBIOPHARM perpetual futures?

Sino Biopharmaceutical Limited (SINOBIOPHARM) perpetual futures trade on 1 crypto venues, including Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade SINOBIOPHARM around the clock?

Yes. Unlike the underlying stock, SINOBIOPHARM perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on SINOBIOPHARM perpetuals?

Right now the SINOBIOPHARM perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to 0.0% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the SINOBIOPHARM perp price compare to the Sino Biopharmaceutical Limited stock?

The venue-median SINOBIOPHARM perp mark is $0.71 versus a reference stock price of $0.71, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a SINOBIOPHARM perpetual future?

A SINOBIOPHARM perpetual is a derivative that tracks the price of Sino Biopharmaceutical Limited with no expiry date. It lets you take long or short exposure to Sino Biopharmaceutical Limited on crypto venues, around the clock.

What is SINOBIOPHARMUSDT perpetual?

SINOBIOPHARMUSDT is the symbol most crypto exchanges use for the Sino Biopharmaceutical Limited perpetual settled in USDT (Tether). It tracks the SINOBIOPHARM share price through an index, trades 24/7 with leverage and never expires.

Other Healthcare perps

Also listed on Gate.io

Embed this asset

SINOBIOPHARM perpetuals · perpequities.comSINOBIOPHARM perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/sinobiopharm-perp"><img src="https://perpequities.com/badge/sinobiopharm-perp.svg" width="240" height="64" alt="SINOBIOPHARM perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Next step

Stay on top of SINOBIOPHARM perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for SINOBIOPHARM — one email every Sunday.

Watchlist and alerts

Price and funding alerts for SINOBIOPHARM, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X